Join the launch of the
Drug Discovery & Development Venture Builder -
where bold ideas meet real support.
10-Sep-2025 | JADS Kapel in 's-Hertogenbosch
Why attend?
This event is your gateway to:
- Discovering the future of innovation: Learn how this programme is set to catalyze Drug Discovery and Development companies (alt. how we turn early ideas into investment-ready companies)
- Networking with key players: Meet venture capitalists, tech transfer professionals, founders, and innovators shaping the future of drug discovery and development.
- Exploring opportunities: Gain insights into the programme’s structured pipeline of ventures, from early-stage feasibility studies to scalable, investment-ready companies.
- Engaging with Experts: Hear from pioneers in the field about how this programme will unlock the untapped innovation potential of the Netherlands.
What's on the agenda
- Visionary insights from leaders in biotech, venture capital, and innovation.
- Panel talks and practical strategies for early-stage drug development hurdles.
- Venture showcases: meet the first cohort - pitch sessions and one-to-one meeting slots.
- Networking, drinks and dinner: Connect with like-minded professionals over drinks and good food.
Programme
15.30 - 16.00 Walk in
16.00 - 16.05 Welcome by Brabant Development Agency (BOM)
16.05 - 16.35 Keynote: Today's Challenging Biotech Industry by Melanie Senior - Biopharmaceutical industry analyst & reporter
16.35 - 16.55 The Successes and Challanges of an Entrepeneur by Maarten Ligtenberg - CEO of Flindr Therapeutics
16.55 - 17.05 Unveiling the DD&D Programme by Britta Driessen - Venture Developer at BOM
17.05 - 17.30 Panel discussion: insight & opportunities
17.30 - 19.30 Networkingdrinks & dinner
Who will benefit
- Entrepreneurs: Learn how to accelerate your journey from concept to commercialization.
- Venture capitalists: Discover promising investment opportunities in the DD&D space.
- Tech transfer professionals: Explore how this programme bridges the gap between academia and industry.
Source: 3D-PharmXchange, Odgers and Brabant Development Agency (BOM)